Against Malaria
Malaria cases by country (6) |
Life cycle of plasmodium falciparum (7) |
The most effective vaccine will be
one that targets the sporozoite while humans are still asymptomatic; this is
when the sporozoite has not yet spread from the liver to the blood (3). The World
Health Organization has set a goal of obtaining a vaccine that is 80% effective
by 2025. However, despite years of research and development, no current
vaccines reach this level of efficacy. Currently the only way to confer
protective immunity against malaria is by injecting people with inactivated
sporozoites from >1000 mosquitos (the inactivation of the sporozoite is done
by irradiation). Clearly, breeding this many mosquitos and isolating
sporozoites from each one is not an optimal means of vaccination. As a result,
a research group developed a way to grow radiation-attenuated Pf sporozoites
(PfSPZ). The researchers attempted to vaccinate people subcutaneously, under
the skin, but this method only caused minimal immune response and very low
protective immunity. Recently however, the same group of researchers found that
injecting PfSPZ intravenously (IV) provides protective immunity against malaria.
The recent study used a vaccine
with various doses of PfSPZ and injected it intravenously multiple times over
the course of several weeks. The study participants, termed vacinees, were
infected with controlled human malarial infection (CHMI), which involves giving
a low dose of sporozoites and intervening with anti-malarial medications as
soon as patients become symptomatic. There
were three study groups, with control individuals in each group whom did not
receive the vaccine but were infected with CHMI. The three groups of vacinees
received three different doses of PfSPZ, and varied in the number of vaccines
of each dose administered. While protection was low in the group receiving the
lowest dose, there was significant protection against malaria infection in the
group receiving the highest dose of PfSPZ. In the group that received the
highest concentration of PfSPZ per dose, 1.35 X 105, and were
administered the vaccine four or five times provided 66% and 100% protection
against CHMI respectively. These results were promising, so the researchers
then looked to see what types of immune responses were being elicited that were
providing protection against CHMI.
One
component of the immune system that the researchers examined was the antibody
response. Antibodies are proteins specific for a pathogen that are secreted by
a certain type of immune cell called a B cell, and bind to the target pathogen
to inactivate them, usually by blocking the function of key pathogen proteins. The
researchers drew blood from the vacinees, isolated the antibodies, and
quantified the number of antibodies. The concentration of PfSPZs-specific
antibodies increased with increasing dose of the PfSPZ vaccine. The researchers
did not find any antibodies against malaria sporozoite that infects red blood
cells, indicating that the vaccinated individual’s sporozoites did not develop
past the liver stage.
In addition
to looking at the antibody response, the researchers looked at the immune
cell-mediated response since it is understood that full protective immunity
against malaria requires cellular immunity. Specifically CD8+ T cells, which
kill infected cells, and interferon-Υ (IFN-Υ), a signaling molecule that enhances
the CD8+ T cell response, are critical for protective immunity against malaria.
The investigators looked at the percentage of immune cells that were CD8+ T
cells and that were also secreting only IFN-Υ to see if there was a difference
in the fraction of immune cells meeting this criteria between protected and
infected individuals. Indeed, people who received the highest dose of PfSPZ and
were protected against malaria had a much higher portion of their immune cells
that were CD8+ and secreted IFN-Υ. This reinforces the understanding that the
cell-mediated immune response is critical for fighting and protecting against
malaria.
This is the first
time that a malaria vaccine has achieved such high protection since the
discovery that protection can be elicited by >1000 mosquito bites. The group
that received the highest dose of PfSPZ had full protection against malaria.
While this study was successful, more clinical trials need to be carried out
before vaccine development can start. In order to optimize the vaccine’s
protective function, different numbers of doses, and time between doses needs
to be investigated to determine how to provide the greatest protection. In
addition, clinical trials need to include more people, as this trial only had
57 subjects. Regardless of the need for further research, these findings
provide new hope that the production of a malaria vaccine is on the horizon.
For more information on Malaria visit:
http://www.cdc.gov/malaria/
http://www.who.int/topics/malaria/en/
Works Cited
2. World Health Organization, World Malaria Report: 2012;
available at
www.who.int/malaria/publications_world_malaria_report_2012/report/en/index.html.
3. Plowe, C.V., Alonso, P., & Hoffman, L. (2009). The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J. Infect. Dis., 200, 1646-1649.
Picture Sources
4. http://www.mr4.org/
5. http://www.plosbiology.org/article/browseIssue.action?issue=info:doi/10.1371/issue.pbio.v03.i06
6. http://keepingkidssafenow.info/disease/malaria-map-cdc-2/
7. http://www.niaid.nih.gov/topics/malaria/pages/lifecycle.aspx
No comments:
Post a Comment